B细胞成熟抗原与CD19嵌合抗原受体T细胞联合治疗多发性骨髓瘤的长期随访
这项单臂II期试验评估了抗B细胞成熟抗原(BCMA)与抗CD19嵌合抗原受体(CAR)T细胞联合治疗复发/难治多发性骨髓瘤(R/R MM)的长期结局。62例接受联合输注的患者中,总缓解率为92%(57/62),完全缓解或更好为60%(37例),中位无进展生存期为18.3个月(95%CI 9.9-26.7),中位总生存期未达到。结论认为该联合方案可诱导持久缓解,长期安全性可控。
要点
- 抗BCMA与抗CD19 CAR T细胞联合输注后总缓解率92%(57/62),完全缓解或更好60%(37例)。
- 中位无进展生存期18.3个月(95%CI 9.9-26.7),中位总生存期未达到。
- 细胞因子释放综合征发生率95%(59例),3级及以上占10%;神经毒性事件11%(7例),3级及以上占3%。
核心结论
- 抗BCMA与抗CD19 CAR T细胞联合治疗在R/R MM患者中诱导持久缓解,中位无进展生存期18.3个月,长期安全性可控。
研究设计与样本
- 单臂II期试验,纳入69例R/R MM患者,其中62例接受抗BCMA与抗CD19 CAR T细胞联合输注,输注剂量为1×10^6 cells/kg,预处理化疗为环磷酰胺联合氟达拉滨。
主要发现
- 中位随访21.3个月,总缓解率92%(57/62),完全缓解或更好60%(37例),可检测微小残留病灶的患者中77%(43/56)确认微小残留病灶阴性。
- 估计中位缓解持续时间20.3个月(95%CI 9.1-31.5),中位无进展生存期18.3个月(95%CI 9.9-26.7),中位总生存期未达到。
- 伴髓外病变的患者生存显著更差。
- 细胞因子释放综合征发生59例(95%),3级及以上占10%;神经毒性事件7例(11%),3级及以上占3%。
- 晚期不良事件少见,除B细胞发育不全、低丙种球蛋白血症和感染外。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A combination of anti-B-cell maturation antigen (BCMA) and anti-CD19 chimeric antigen receptor (CAR) T cells induced high response rates in patients with relapsed or refractory (R/R) multiple myeloma (MM), but long-term outcomes have not been assessed yet. PATIENTS AND METHODS: In this single-arm, phase II trial, patients with R/R MM received a combination of anti-BCMA CAR T cells and anti-CD19 CAR T cells at a dose of 1 × 106 cells/kg, after receiving a conditioning chemotherapy consisting of cyclophosphamide and fludarabine. The overall response, long-term outcomes, and safety were assessed, as were their associations with clinical and disease characteristics. RESULTS: Of 69 enrolled patients, 62 received the combined infusion of anti-BCMA and anti-CD19 CAR T cells with a median follow-up of 21.3 months. The overall response rate was 92% (57/62), and complete response or better was observed in 37 patients (60%). Minimal residual disease-negativity was confirmed in 77% (43/56) of the patients with available minimal residual disease detection. The estimated median duration of response was 20.3 months (95% CI, 9.1 to 31.5). The median progression-free survival was 18.3 months (95% CI, 9.9 to 26.7), and the median overall survival was not reached. Patients with extramedullary disease had significantly inferior survival. Fifty-nine patients (95%) had cytokine release syndrome, with 10% grade 3 or higher. Neurotoxic events occurred in seven patients (11%), including 3% grade 3 or higher. Late adverse effects were rare, except for B-cell aplasia, hypogammaglobulinemia, and infections. CONCLUSION: The combination of anti-BCMA and anti-CD19 CAR T cells induced durable response in patients with R/R MM, with a median progression-free survival of 18.3 months and a manageable long-term safety profile.
引用
- Wang Y, Cao J, Gu W, et al. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol. 2022. PMID: 35333600. doi:10.1200/JCO.21.01676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。